Quick Answer
Aurinia Pharmaceuticals Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $283.06 million for the year ending 2025.
- Aurinia Pharmaceuticals Inc. showed an increase of +20.4% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Aurinia Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 8 years of available data (2018 to 2025), Aurinia Pharmaceuticals Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 61,035.0%.
- Historical annual values: Fiscal year 2025: $283.06 million | Fiscal year 2024: $235.13 million | Fiscal year 2023: $175.51 million | Fiscal year 2022: $134.03 million | Fiscal year 2021: $45.61 million | Fiscal year 2020: $50.12 million | Fiscal year 2019: $318.0 thousand | Fiscal year 2018: $463.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 24, 2026.
Last verified: